These experiments utilized CDX2-CreERT2:α3flx/flx mice generated through the above-described intercross (Figure 1a) that did not carry the KrasG12D oncogene and were Apc+/+ (i.e., these mice were not susceptible to colorectal dysplasia or cancer following tamoxifen treatment). This evidence concerns the gene CDX2 and cancer.